Method for synthesis of s-enantiomeric derivatives of glutaramide or theirs pharmaceutically accepta

专利摘要:
S Enantiomeric diuretic agent of the formula: <CHEM> wherein each R and R<4> is H or one of R and R<4> is H and the other is a biolabile ester group, a process for their preparation and intermediates therefor.
公开号:SU1766251A3
申请号:SU4614002
申请日:1989-05-17
公开日:1992-09-30
发明作者:Кристофер Данилевич Джон；Тревильян Вилльямс Майкл
申请人:Пфайзер Инк (Фирма)；
IPC主号:

专利说明:

This invention relates to organic chemistry, namely to a method for producing S-enantiomeric glutaramide derivatives of the formula
BUT, with
Sn3cen2sn2o-sn
 9
-s-snl
CONH-Octyj,
or their pharmaceutically acceptable salts, where each of the radicals R and RI is H, or R is 5-indanyl, said enantiomer contains less than 10% of the R-enantiomer, which are inhibitors of the neutral endopeptidase E.C. 3.4.4.24.11 and can not be used in various therapeutic areas, including the treatment of various cardiovascular diseases, such as hypertension and heart failure.
There are known (K, 3) -enantiomeric derivatives of glutaramide, which also have the ability to inhibit endopeptidase E.C.3.4.24.11, but this ability is not high enough.
The aim of the invention is to develop an accessible method for the preparation of compounds I which, by inhibiting neutral endopeptidase E.C. 3.4.24.11, can enhance the effect of ANF (arterial natriuretic factor).
with
This goal is achieved by the described methods for the preparation of S-enantiomeric glutaramide derivatives of general formula I by the interaction of a compound of formula
 Q
R202C-C-CH2 C02H, CH3OCHNCH2OCH2
where R2 is lower alkyl, a group of M-acetyl- (1R.2S) - complex ephedrine ester or 5-indanyl, with a compound of the formula
NgM-O 00
where Pz is lower alkyl or benzyl, followed by cleavage of the radicals R2 and Pz to obtain compound I, where R and RI are hydrogen, or by cleaving the radical Ra to obtain compound I, where Ri is hydrogen; R2 is R and is 5-indanyl, or with cleavage of the R2 radical meaning lower alkyl, followed by esterification of the product with 5-indanyl and cleavage of the RS radical to give compound I, where RI is hydrogen. R -5-indanyl.
The invention is illustrated by the following examples.
Example 1. (25) - (2-Methoxyethoxymethyl) (phenacyloxycarbonyl) cyclopentyl propanoic acid M-acetyl- (1P, 25) is an ephedrine ester.
L, M-Dicyclohexylcarbodiimide (5.66 g, 24.5 mmol) was added to an ice-cooled, stirred solution of N-acetyl- (III, 25) -ephedrine (4.24 g 20.46 mmol), 2- ( 2-methoxyethoxymethyl) (fenacilloxycarbonyl) cyclopentyl propane acid (8.43 g, 21.48 mmol) and 4-dimethylaminopiridine (1.23 g, 10 mmol) in dry methylene chloride (100 ml). After 1 h, the solution is allowed to warm to ambient temperature and stirred for 2.5 days. The suspension is filtered, the solvent is evaporated off under reduced pressure and the residue is treated with diethyl ether and water. The organic layer is sequentially washed with 0.5 n. hydrochloric acid, water, saturated aqueous bicarbonate solution and water. After drying (MgOl) and evaporation, a crude mixture of diastereoisomers is obtained in the form of an oil (12.5 g), which is passed through a chromatography column with silica, eluting with hexane containing an increasing amount of ethyl acetate (from 4: 6 to 1: 9). More quickly washed out component, having
Rf 0.45 (silica, ethyl acetate) is the target diastereomer and is obtained after evaporation of the appropriate fractions as a resin.
(5.21 g; 44%), 5 - 34.1, ofees 25 - 111.0 ° (c 1.0; CH2CI2). Found,%: 68.19; H 7.59; N 2.46. SzzN4z08 requires C 68.14; H 7.45; N 2.41%.
Another diastereoisomer had a Rf of 0.35
(silica; ethyl acetate); -21.5 °,
 25-67.3 ° (c 1.0; CH2Ci2).
Example 2. (25) - (2-Methoxyethoxymethyl) -3- (1-carboxchcyclopentyl) lropane
acids M-acetyl- (1P, 23) -sulfon of epadri-ester.
A solution of 1M-acetyl (1K, 25) -s (23) - (2-methoxyethoxymethyl) -3-1- (phenacyloxycarbonyl) cyclopentyl propanoic acid (5.17 g, 8.89 mmol) of false ephedrine ester (23) - acetic acid (40 ml) is mixed with activated zinc powder (3 g, 47.7 mmol) at room temperature under a nitrogen atmosphere in
for 2 hours. The mixture is filtered and the filtrate is evaporated to dryness under vacuum, traces of acetic acid are removed using azeotropic mixture with toluene. The residue is dissolved in dithyl ether and ovortor
extracted with 1 n. sodium hydroxide solution (12 ml) and washed with water. The combined extralts are acidified with concentrated hydrochloric acid / extracted with diethyl ether. Essential Extracts
washed with a saturated solution of salt, dried (MgSO / O and evaporated, resulting in obtaining the target product as a thick oil (4.03 g, 98%). Found,%: C 63.96; H 8.21; N 2, 87. СазНзтМО (0,3 Н20)
requires C 64.03; H 8.08: N 2.99%.
-34.9 °, and Зб525-115,4 ° (с 1.03,),
Example 3. 3- {1- {cis-4-3-methoxycyclobenzylcyclohexyl) carbamoyl – tsucs enyl} (25) - 2-methoxy latoximyl (propanoic acid M-acetyl-) 1P, 25 is a complex ephesrin-ester.
Hydrochloride of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (3.32 g 17.34
mmol) is added to an ice-cooled stirred mixture of the product from example 2 (3.98 g, 8.58 mmol), cis-4-aminocyclohexanecarboxylic acid ethyl ester hydrochloride (2.70 g, 13
mmol) 1-hydroxybenzotriazole (1.17 g. 8.67 mmol) and N-methylmorpholine (H 07. g, 30.34 mmol) in dry methylene chloride (30 ml). After 15 minutes the mixture is allowed to warm to room temperature and left to stand overnight. The solvent is evaporated off under a vacuum. J
CM
fo io g- -wn-.-r ,,
.YCRLO ;:
sg n: a.; -.
ЈX -.OS
fe th ° Co
xo
h.v- ii -;.,
s52s
);)% .c-bcb
iSodioO-0-OSL
Ј tQ-; -c.
"...- 5Ј ™" u n5E: T2
; -: ti (.
:; ; ./; vi l- - .- -; - g, -co. .i; P- 5 ™ "J o.-d with
to L, .. g .. „... o (;; .-;; / i i. i- a) Q.Cl ..- it - S; 5 i ° Г; c
  -; -; -, 1 I:, 2.:.;5- 55 | 3iнra о. Iss G
about
o-i-ij - ;;:, - - S- - S / ::. p. fi
- “m., - i ° j: y :: g- b
  y. ... ™
I
 1 P h
V. - at i6 ::
X - f- Q. P
9 F .i; S4 3 o - | nd
 and about with; about S -S about and; to about with. ; s ga
After filtering for drying, a crude (+) - pseudosedphonic salt of (3) -acids (4.0 g, 60%) is obtained as a white crystalline substance. M.p. 98-102 ° C. After recrystallization, 3.5 g of this material is obtained from a mixture of toluene (10.5 ml) and ethyl acetate (10.5 ml) (+} - pseudoephedrine salt of the indicated compound (2.2 g, yield 62.8 %) as white crystals, mp: 111.3 ° C, + 25.1 ° (c 5. MeOH). Found: C 69.19; H 8.20; N 2.38. C32H45N07 requires C 69 , 16; H 8.15; N 2.51%.
A sample of this salt (2 g) is suspended in a mixture of hexane (5 ml), ethyl acetate (5 ml) and water (10 ml), then concentrated hydrochloric acid is added dropwise to bring the pH of the aqueous phase to 1.5%. . The two phases of the solution are separated and the aqueous phase is washed with a mixture of ethyl acetate: hexane 1: 1 (10 ml). After evaporation of the combined organic layers, the indicated compound is obtained as a colorless oil (1.2 g, 85% from salt), 50 (c 5, MeOH), Rf 0.41 (silica; toluene, acetic acid 8: 2). Found,%: C, 67.25; H 7.77. According to the calculation for C22H3Ob: C 67.67; H 7.74%. Method: the irradiated NMR of this product showed that it is practically pure S-engineering. containing only 4% R zngnt :. measure.
Example 8, (3) -Benzyl - cis-4- {1-, x ,; indanyloxycarbonyl) - 3- (2-methox1-, stoxix) propyl -1-cyclolentanecarboxamido} - i cyclohexanecarboxylate.
Hydrochloride 1- (3-dimethylaminophenol-3) -3-methylcarbodiimide (337.5 mg, 1.76 mmol) is added to the stirred solution of (3) (5-indignyloxyxrbonyl) -3- (2-m ets about c and eto about c with i) - l r o p and l - 1 - cyclopentanecarboxylic acid (625: -l 1.6 mmol), benzyl cis-4-amino-1-cyclohexanecarboxylate p- Toluenesulfonates (700 mg. 1.73 mmol), β-oxibenzotriazole hydrate (240 mg, 1.78 mmсl) and 1-methylmorphol :: -; (560 mg, 5.5 mmol) in methylene chloride (3.75 ml). The solution is stirred at ambient temperature for 18 h, evaporated under vacuum and the residue is treated with diethyl ether and water. The organic extract is successively washed with 1 p. Of hydrochloric acid, saturated with water, -.-. bicarbonate solution and water. After drying (MgSO4) and evaporation, I get 1 oil (0.9 g), which is passed through a chromatography column with silica (25 g), eluting with hexane containing an increasing amount of ethyl acetate (from 4: 1 to 3: 1), whereby they get cele
with;

 -
Jaffna complex as it is extracts (830 mg, 36%), 3.3 ° (c 1, MeOH), Rf 0.52 (silica; ethyl acetate). Found,%; C, 70.32; H7.74; N2,19. According to the calculation for CGsri NOyfO.S H20) C 70.33; H 7.87; H 2.28%.
Example 9, (3) -cis-4-M- | - (5-Indzy-loxmcarbonyl) - 3- (2-methoxy-toxy) - prc-p and l-1 - cyclop 8 n t a n c s p 5 o k Ј m and up to} - - tsujlskhekshn carbolic acid.
RISTVOR 3) - (cis-4-lp-s-iHAS- niloxykerbOg: yl) -3- (2-methoxy toxiPropyl -1-kg / clopent: n ;; sprhox M1 1dg (-1-: Ch1klghexaccharboxy -.at (597, 0.986 mol) in 5% water, anole (0} gich11 r - /: g over 10% palladium nor oct / ooE.chno, .-; e e quality rolls Zatoi (60 mg np-i pressure 4.1 bar and room temperature B for 3.5 hours. The catalyst is filtered and the filters are evaporated under raluu, see Residue &amp; g in diethyl; eF1-: re (50 ml), and the solution is clarified they are nute.- .., o:; a- ni, concentrated to chalpg; o6o.-j. ir (mg - g, about 5 ml), in razultztch chags, kristallz1 .. After all; re -: - a | -.and -vilts-V-. eeves -. / shizani get y:; azznny complex -.- rir (390; -1.; s 5e /; b: x cri- g; alls 3. So:;.. J7-S 0:.; i: -5.3 (c- 1. iv ieOH),. 1GfoKCi ..: - r :-p: ;; v -.;: - .-. MUS-. Gorky has a potential gas dredger TOpro v;. D Gu rETICHVSK-irv;. /. NSTDI / p &amp; T:: o. J K AND, V:
de /; ogzie; Tz (, l - g: l5iou neutral-i-- / y zi; dopeptidzu EG3.4.24 11, compounds t13G &amp; p pg, ivioryT will strengthen onols siche action of ANF, c - ac: carry, soy de-iso &amp; arthritis are. | .1ure: o.: am: - cnoi: .3yeivibiMn rc best, -n-i with -.- db zab lev- Hi / ii /, nklong: - hypertension,: cardiac failure, sore throat, renal insufficiency, premenstrual cider, cyclical edema, Maenaa disease, hype-5 /;,; osgro: -: e; - 0: .-; (first, i; atoric; d)
Here. ; - i: i (.- JOCO & HC-rT /; yCW / fi / iSSTo ACTION Af i: -. С06.TIRTICLE: I; 5300РвТв -, ИЯ I f O / ibSVXJT
r, pi.-i treatment of glazcoma. Others; g; teeth / 1yatom abilities :: - 1ng.-1svat neutral neutrino en-. ; 0.ep7idase E.G.3.4.24.11 due to the fact that, with the invention of the invention, there may be chrfexgia in other areas of therapy,
including, for example, the treatment of asthma, inflammatory processes, pain, epilepsy, functional impairment, dementia and geriatric mixing, obesity and gastrointestinal disorders (especially diarrhea and intestinal syndrome), reduction of gastric juice and treatment of hypertension.
Data on the activity shown in the table.
The activity of the racemate and the individual enantiomers of cis-4- {1- 2-carboxy-3- (2- methoxmethoxm), drank -1 - cyclopentane-carboxamido} -1-cycle ore xancarboxylic acid was evaluated by their ability to inhibit neutral endopeptidase E.C. .3.4.24.11 in vitro or induce natuoethitis in mice in vivo.
Thus, an active species is a compound having a stereochemistry of S. This is demonstrated by the ratio of dicarboxylic acid, where R and RI mean I. The indznyl ester is a biolabile ester derivative, which acquires its biological activity after in vivo hydrolysis to produce dccarboxylic acid.
The compounds of the invention may be considered as low toxic, currently tested in humans at dosages of up to 10 g / kg without any indication of negative toxic effects.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining the S-enantiomeric derivatives of glutaramide of General formula
 Q
RO C-C-CH /:
sn3bn, sn2o-sn2
 CONH- {C02Rf
or their pharmaceutically acceptable salts, where each of R and RI is H or R is 5-indanyl, with the specified enantiomer contains less than 10% P-known; - Omer. wherein the S-enantiomeric compound of formula H
 ABOUT
R202C-C-CH7XC0, H.
СН3ОСН2СН2ОеН,
where R2 is a lower alkyl, a group of M-acetyl- (1P, 25) -complicated new ester or B-indyl.
subjected to interaction with the compound of formula 1P
H2 KI / teC02R
B
 From lower alkyl or benzyl, followed by cleavage of the R2 and P3 radicals to form a compound, where R and RI are hydrogen, or cleavage of the Cz radical to form a compound, where R; - hydrogen, a and means 5-upsyl, or with cleavage of the radical R2, meaning lower aryl, followed by esterification of the product with 5-ina-anol and squeezing the radical Ra according to (i) learning of compound i, where RI is hydrogen, and R 5-indanyl.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AP1116A|2002-10-21|Bicyclo [2.2.] heptanes and related compounds.

---

SU1766251A3|1992-09-30|Method for synthesis of s-enantiomeric derivatives of glutaramide or theirs pharmaceutically acceptable salts

---

US3920728A|1975-11-18|Separation and resolution of isomeric forms of 3-|-serine

---

JPH0645584B2|1994-06-15|N- | cycloalkylcarbonyl) -beta-alanine derivative for pharmaceuticals

---

WO1992014706A1|1992-09-03|Cyclopentane-derived glutaramide antihypertensive agents

---

DD283807A5|1990-10-24|PROCESS FOR PREPARING CYCLOALKYL SUBSTITUTED GLUTARAMIDE DERIVATIVES

---

US5068412A|1991-11-26|-α-|glycine

---

US4785089A|1988-11-15|Novel sulfonic acid esters and their preparation

---

EP0144980B1|1989-07-12|Process for the preparation of optically active 3-aminocarboxylic acids |

---

DE2660626C2|1985-07-11|3-Amino-2-hydroxy-4-phenyl-butanoic acid derivatives and process for their preparation

---

AU610294B2|1991-05-16|Amino acid esters of 4-alkoxy-5-arylhydroxymethyl-2-|- furanone

---

US4490386A|1984-12-25|Phosphate salts of 1-[2-[|-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof

---

DE3625738A1|1988-02-11|2-ACYLOXYPROPYLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND THEIR USE

---

EP0907633A1|1999-04-14|New synthetic catechol derivatives, method for production and use thereof

---

IE910083A1|1991-07-17|Cycloalkyl-substituted glutaramide diuretic agents

---

DE3323871A1|1985-01-03|NEW 1-O-ALKYL-3-AMINO-PROPAN-1,2-DIOL-2-O-PHOSPHOLIPIDES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

---

DE602004007265T2|2008-02-28|PROCESS FOR THE PREPARATION OF PERINDOPRIL USING TETRAMETHYLURONIUM SALTS AS COUPLING REAGENTS

---

US3470233A|1969-09-30|Process for the manufacture of l-|-beta-|-alpha-methylalanine

---

WO1992011234A1|1992-07-09|Novel amines, process for producing them and medicaments containing said compounds

---

WO1990009374A1|1990-08-23|Cycloalkyl-substituted glutaramide diuretic agents

---

SU1189859A1|1985-11-07|Chiral derivatives of |-or |-2-n-|-aminobenzophenone as reagent for producing optical isomers of alpha-aminoacids

---

JP2002535302A|2002-10-22|Method for synthesizing compound of formula 1 and derivatives thereof

---

US4866173A|1989-09-12|Therapeutic substituted semicarbazides

---

AT406372B|2000-04-25|LYSINE-PROLIN DERIVATIVES

---

EP0385423B1|1995-02-08|Process for the preparation of the optical isomers of 1,4-dihydro-5-isopropoxy-2-methyl-4-|-1,6-naphthyridine-3-carboxylic-acid ethyl ester and 1,4-dihydro-5-isopropoxy-2-methyl-4-|-1,6-naphthyridine-3-carboxylic-acid-2-| ethyl ester

同族专利:

---

公开号 | 公开日

---

DK172032B1|1997-09-22|

---

PH26740A|1992-09-28|

---

NO892002D0|1989-05-18|

---

NZ229186A|1990-10-26|

---

AT76399T|1992-06-15|

---

GR3004968T3|1993-04-28|

---

AU602813B2|1990-10-25|

---

CN1015361B|1992-02-05|

---

AU3490489A|1989-11-23|

---

DD283772A5|1990-10-24|

---

YU102289A|1991-06-30|

---

EP0342850B1|1992-05-20|

---

PT90584B|1994-09-30|

---

JPH072699B2|1995-01-18|

---

CA1331197C|1994-08-02|

---

CS296589A2|1990-09-12|

---

IL90267D0|1989-12-15|

---

HU205067B|1992-03-30|

---

GB8811873D0|1988-06-22|

---

NO173647B|1993-10-04|

---

CN1037704A|1989-12-06|

---

NO173647C|1994-01-12|

---

KR900017993A|1990-12-20|

---

KR920000561B1|1992-01-16|

---

IE60724B1|1994-08-10|

---

PT90584A|1989-11-30|

---

CS274502B2|1991-04-11|

---

IE891613L|1989-11-19|

---

FI892386A0|1989-05-18|

---

JPH0222256A|1990-01-25|

---

FI892386A|1989-11-20|

---

FI93541B|1995-01-13|

---

DK240889A|1989-11-20|

---

DK240889D0|1989-05-18|

---

ES2037418T3|1993-06-16|

---

HUT53596A|1990-11-28|

---

IL90267A|1993-08-18|

---

EG19007A|1994-11-30|

---

ZA893696B|1990-12-28|

---

FI93541C|1995-04-25|

---

EP0342850A1|1989-11-23|

---

PL279491A1|1989-11-27|

---

DE68901582D1|1992-06-25|

---

PL154813B1|1991-09-30|

---

NO892002L|1989-11-20|

---

MY104735A|1994-05-31|

---

MX16067A|1993-10-01|

---

YU47973B|1996-08-13|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

KR880007441A|1986-12-11|1988-08-27|알렌 제이.스피겔|Spiro-Substituted Glutaramide Diuretics|GB8812597D0|1988-05-27|1988-06-29|Pfizer Ltd|Therapeutic agents|

---

GB8820844D0|1988-09-05|1988-10-05|Pfizer Ltd|Therapeutic agents|

---

GB9000725D0|1990-01-12|1990-03-14|Pfizer Ltd|Therapeutic agents|

---

AT130292T|1993-09-22|1995-12-15|Pfizer Res & Dev|HYDRATION.|

---

US7468390B2|2002-01-17|2008-12-23|Novartis Ag|Methods of treatment and pharmaceutical composition|

---

AR057882A1|2005-11-09|2007-12-26|Novartis Ag|DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS|

---

US8993631B2|2010-11-16|2015-03-31|Novartis Ag|Method of treating contrast-induced nephropathy|

---

BR112015003067A2|2012-08-24|2017-07-04|Novartis Ag|nep inhibitors to treat diseases characterized by atrial enlargement or remodeling|

---

WO2017033128A1|2015-08-25|2017-03-02|Novartis Ag|Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors|

---

WO2017072636A1|2015-10-29|2017-05-04|Cadila Healthcare Limited|Pharmaceutical synergistic combination|

法律状态:
2005-05-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20040518 |

优先权:

---

申请号 | 申请日 | 专利标题

---

GB888811873A|GB8811873D0|1988-05-19|1988-05-19|Therapeutic agents|

---